These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24852232)

  • 1. Monoamine oxidase and α-synuclein as targets in Parkinson's disease therapy.
    Follmer C
    Expert Rev Neurother; 2014 Jun; 14(6):703-16. PubMed ID: 24852232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
    Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
    J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson's disease.
    Naoi M; Maruyama W; Shamoto-Nagai M; Riederer P
    J Neural Transm (Vienna); 2024 Jun; 131(6):639-661. PubMed ID: 38196001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
    Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ
    Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degeneration of dopaminergic neurons induced by thrombin injection in the substantia nigra of the rat is enhanced by dexamethasone: role of monoamine oxidase enzyme.
    Argüelles S; Herrera AJ; Carreño-Müller E; de Pablos RM; Villarán RF; Espinosa-Oliva AM; Machado A; Cano J
    Neurotoxicology; 2010 Jan; 31(1):55-66. PubMed ID: 19969022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease.
    Kang SS; Ahn EH; Zhang Z; Liu X; Manfredsson FP; Sandoval IM; Dhakal S; Iuvone PM; Cao X; Ye K
    EMBO J; 2018 Jun; 37(12):. PubMed ID: 29769405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease.
    Sass MB; Lorenz AN; Green RL; Coleman RA
    J Neurosci Methods; 2009 Apr; 178(2):366-77. PubMed ID: 19136028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
    Galvin JE
    Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.
    Unzeta M; Sanz E
    Int Rev Neurobiol; 2011; 100():217-36. PubMed ID: 21971010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geraniol attenuates α-synuclein expression and neuromuscular impairment through increase dopamine content in MPTP intoxicated mice by dose dependent manner.
    Rekha KR; Selvakumar GP; Santha K; Inmozhi Sivakamasundari R
    Biochem Biophys Res Commun; 2013 Nov; 440(4):664-70. PubMed ID: 24103762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease.
    Woodard CM; Campos BA; Kuo SH; Nirenberg MJ; Nestor MW; Zimmer M; Mosharov EV; Sulzer D; Zhou H; Paull D; Clark L; Schadt EE; Sardi SP; Rubin L; Eggan K; Brock M; Lipnick S; Rao M; Chang S; Li A; Noggle SA
    Cell Rep; 2014 Nov; 9(4):1173-82. PubMed ID: 25456120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary Natural Flavonoids: Intervention for MAO-B Against Parkinson's Disease.
    Singh A; Sinha S; Singh NK
    Chem Biol Drug Des; 2024 Sep; 104(3):e14619. PubMed ID: 39223743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective and toxic roles of dopamine in Parkinson's disease.
    Segura-Aguilar J; Paris I; Muñoz P; Ferrari E; Zecca L; Zucca FA
    J Neurochem; 2014 Jun; 129(6):898-915. PubMed ID: 24548101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease.
    Sternic N; Kacar A; Filipovic S; Svetel M; Kostic VS
    Clin Neuropharmacol; 1998; 21(2):93-6. PubMed ID: 9579294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
    Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
    Koo HJ; Choi MY; Im H
    Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species.
    Braga CA; Follmer C; Palhano FL; Khattar E; Freitas MS; Romão L; Di Giovanni S; Lashuel HA; Silva JL; Foguel D
    J Mol Biol; 2011 Jan; 405(1):254-73. PubMed ID: 21050861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson's disease.
    Jadiya P; Khan A; Sammi SR; Kaur S; Mir SS; Nazir A
    Biochem Biophys Res Commun; 2011 Oct; 413(4):605-10. PubMed ID: 21925152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.